康龍化成(300759.SZ):擬不超1.375億美元收購AS及其子公司ASC和ASB的100%股權
格隆匯11月9日丨康龍化成(300759.SZ)公佈,公司擬以自有資金不超過1.375億美元(其中1.15億美元為股權轉讓基本交易價款,不超過2250萬美元為價格調整機制)收購Absorption Holdings LLC (“AH”或“賣方”)所持有的Absorption Systems LLC (“AS”)及AS的全資子公司Absorption Systems California LLC (“ASC”)和Absorption Systems Boston LLC (“ASB”)的100%股權。此次交易完成後,公司將通過全資子公司Pharmaron (US) Lab Testing, Inc.持有AS公司的100%股權,並通過AS公司間接持有ASC和ASB公司的100%股權。
標的公司及其全資子公司,為大分子/小分子藥物、基因治療、細胞療法及醫療器械產品提供非臨牀體外和體內實驗室分析、生物學測試和動物測試服務,以支持相關藥物、療法及醫療器械產品的發現、開發和審批。
AS及其全資子公司ASB和ASC的合併財務數據,截至2018年12月31日/2018年度,未經審計合併報表的營業收入、營業利潤、税前利潤和淨利潤分別是:3513.9萬美元、532.3萬美元、511.5萬美元和368.3萬美元。
公司的核心發展戰略是持續打造並不斷完善深度融合的全流程一體化和國際化的藥物研發服務平台。為此,公司需進一步加強全流程一體化服務平台的建設並繼續加強全球化佈局,此次收購有利於公司更好地整合資源,完善全流程一體化平台建設,符合公司長遠發展規劃及全體股東利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.